Sanofi strong in 1Q despite diabetes slump as Brandicourt starts strategic review
This article was originally published in Scrip
Sanofi's new CEO Olivier Brandicourt was able to report a strong set of first quarter results just a few weeks after taking the helm, which hardly seems fair to ousted CEO Chris Viehbacher. Sanofi's first quarter sales increased by 2% at constant exchange rates to €8.8bn (12% on a reported basis owing to the weak euro), which was above analysts' expectations. However, its diabetes business is still a major concern.